Kostakoglu Lale, Agress Harry, Goldsmith Stanley J
Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital, Weill Cornell Medical Center, 525 E 68th St, Starr No. 221, New York, NY 10021, USA.
Radiographics. 2003 Mar-Apr;23(2):315-40; quiz 533. doi: 10.1148/rg.232025705.
Positron emission tomography (PET) is a diagnostic imaging technique that allows identification of biochemical and physiologic alterations in tumors. Use of PET performed with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) significantly improves the accuracy of tumor imaging. In terms of oncologic applications, FDG PET has already gained widespread acceptance in the initial staging of cancer, management of recurrent cancer, and monitoring the response to therapy. With conventional imaging modalities, size criteria are used to distinguish between benign and malignant disease in lymph nodes; conversely, FDG PET is based on identification of fundamental aspects of tumor metabolism. FDG uptake in tumors is proportional to the metabolic rate of viable tumor cells, which have an increased demand for glucose. The high sensitivity and high negative predictive value of FDG PET in most malignant tumors enable this technique to play an even greater role in tumor management at initial staging and follow-up.
正电子发射断层扫描（PET）是一种诊断成像技术，可用于识别肿瘤中的生化和生理改变。使用2-[氟-18]氟-2-脱氧-D-葡萄糖（FDG）进行PET检查可显著提高肿瘤成像的准确性。在肿瘤学应用方面，FDG PET已在癌症的初始分期、复发性癌症的管理以及治疗反应监测中得到广泛认可。对于传统成像方式，大小标准用于区分淋巴结中的良性和恶性疾病；相反，FDG PET基于对肿瘤代谢基本特征的识别。肿瘤中FDG的摄取与存活肿瘤细胞的代谢率成正比，而存活肿瘤细胞对葡萄糖的需求增加。FDG PET在大多数恶性肿瘤中具有高敏感性和高阴性预测价值，这使得该技术在初始分期和随访的肿瘤管理中发挥更大作用。
